Inhibikase Therapeutics, Inc. (IKT) — Capital Expenditures

Annual figures by fiscal year, from SEC filings.

2021: $02022: $243.3K2023: $14.2K2024: $02025: $13.4K$13.4K
2021Capital Expenditures (USD)2025
Fiscal YearCapital ExpendituresChange YoY
2025$13.4K
2024$0-100.0%
2023$14.2K-94.1%
2022$243.3K
2021$0